Duncan Mwangi | Research Director
Zoetis

Duncan Mwangi, Research Director, Zoetis

Dr. Duncan Mwangi | Research Director and Head, Mechanistic Biology (Systems Biology, Immunology and Adjuvant Research), Global Therapeutics Research, Zoetis  
Dr. Duncan Mwangi is a Research Director and Head of GTR- Mechanistic Biology within Global Therapeutics Research (GTR), Zoetis R&D, Kalamazoo, Michigan. He is also a member of Zoetis GTR leadership team. He joined Pfizer Animal Health (predecessor of Zoetis) to build the Adjuvant Research Team and support vaccine development programs. He currently leads the Mechanistic Biology group in Zoetis that focusses on identification/development of novel therapeutics, immunomodulators and vaccine adjuvants.  Dr. Mwangi is a leader on understanding the mechanisms by which the innate immune system regulates adaptive immunity and harnessing such mechanisms in the design of novel adjuvants, vaccines and therapeutics. Prior to joining Pfizer Animal Health, Dr. Mwangi was a scientist at the International Livestock Research Institute (ILRI, formerly ILRAD, Nairobi, Kenya) leading several programs in immunology, vaccine antigen identification and adjuvants/delivery systems. Prior to joining ILRI, Dr. Mwangi was a post-doctoral immunologist at International Laboratory for Research in Animal Diseases (ILRAD, Nairobi) and the University of Florida focusing on understanding the immunobiology and identification of candidate vaccines for infectious diseases. Dr Mwangi’s research is published in front line journals such as Infection and Immunity, Parasite Immunology, PNAS, Vaccine, Veterinary Immunology and Immunopathology. Furthermore, he has served on editorial boards, and is a reviewer for several Vaccine and Immunology journals. Dr. Mwangi received his Veterinary degree and MSc degree (Immuno-parasitology) from University of Nairobi, Kenya, and holds a PhD (Immunology) from the University of Edinburgh, Scotland, UK.

Appearances:



December 2 Pre-Congress Workshops @ 13:00

Advances in adjuvant technology for vaccines:

Vaccine adjuvants have been used successfully for decades to enhance the ability to provoke an immune response of weak antigens and improve the overall potency of vaccines. Join this workshop to explore the latest advances in novel adjuvant technology for vaccines, the value of current adjuvants and how to improve them. Topics:·Adjuvant technology and its impact on vaccine development ·Can next generation adjuvants break tolerance to assist in immune oncology?·Deploying adjuvants for special populations ·Combination adjuvants – how should they be designed and what are the risks·Adjuvating live vaccines·Use of receptor agonists in improving existing adjuvants or designing new novel adjuvants for different animal species·Precision adjuvants; tailoring immune activation for next generation vaccines
last published: 20/Aug/19 15:45 GMT

back to speakers

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com